Related Experiment Video
Updated: Dec 6, 2025

Comparative Lesions Analysis Through a Targeted Sequencing Approach
Published on: November 5, 2019
Expanding spectrum of "spitzoid" lesions: a small series of 4 cases with MAP2K1 mutations
K G P Kerckhoffs1, T Aallali2, C A Ambarus3
1Department of Pathology, Maastricht University Medical Center+, Maastricht, The Netherlands. kelly.kerckhoffs@mumc.nl.
Abstract:
The molecular background of a significant proportion of spitzoid neoplasms is still unknown. Recently, activating mutations in MAP2K1 have been described in a few spitzoid lesions, but not in benign Spitz nevi. We report four cases of melanocytic tumors with spitzoid features in which a MAP2K1 mutation was detected. The lesions did not show a single distinct phenotype and ranged from benign to malignant. Two cases resembled desmoplastic Spitz nevi. Based on the combination of morphological, immunohistochemical, and molecular findings, one case was classified as benign, one as probably benign, possibly intermediate low-grade (MELTUMP-melanocytic tumor of unknown malignant potential), one case was classified as intermediate (MELTUMP), and one case was considered a superficial spreading melanoma with spitzoid features. Based on this, we conclude that MAP2K1 mutations can indicate a spitzoid genetic signature and can be found in both benign and malignant spitzoid neoplasms.
Insights
MAP2K1 mutations are found in spitzoid neoplasms, ranging from benign to malignant. These mutations indicate a spitzoid genetic signature, expanding our understanding of these skin tumors.
Area of Science:
- Dermatopathology
- Oncology
- Molecular Biology
Background:
- The molecular basis for many spitzoid neoplasms remains unclear.
- Activating MAP2K1 mutations have been identified in some spitzoid lesions, but not typically in benign Spitz nevi.

